Study Results from Diagnostica Stago Update Understanding of Carcinoid Tumor (Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients…
Study Results from Diagnostica Stago Update Understanding of Carcinoid Tumor (Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective)
By a
The news correspondents obtained a quote from the research from
According to the news reporters, the research concluded: "This model showed that providing access to this first-in-class oral agent would have a minimal budget impact to a US health plan."
For more information on this research see: Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clinical Therapeutics, 2017;39(12):2338-2344. Clinical Therapeutics can be contacted at:
Our news journalists report that additional information may be obtained by contacting
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clinthera.2017.10.019. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
New Mental Health Findings Reported from Salem State University (Behavioral Mental Health: An Emerging Field of Service or an Oxymoron?)
American National Insurance Co Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals: (Jan. 22, 2018)
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News